[Federal Register Volume 88, Number 211 (Thursday, November 2, 2023)]
[Notices]
[Pages 75296-75297]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-24229]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive Patent License: Mutant IDH1 
Inhibitors Useful for Treating Cancer

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Center for Advancing Translational Sciences, an 
institute of the National Institutes of Health, Department of Health 
and Human Services, is contemplating the grant of an Exclusive Patent 
License to practice the inventions embodied in the Patents and Patent 
Applications listed in the SUPPLEMENTARY INFORMATION section of this 
Notice to Platform Pharmaceuticals, Inc. (``Platform Pharma''), 
headquartered in New York, NY.

DATES: Only written comments and/or applications for a license which 
are received by the National Center for Advancing Translational 
Sciences' Office of Strategic Alliances on or before November 17, 2023 
will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, 
and comments relating to the contemplated Exclusive Patent License 
should be directed to: Sury Vepa, Ph.D., J.D., Senior Licensing and 
Patenting Manager, Office of Strategic Alliances, Telephone: (301)-642-
0460; Email: [email protected].

SUPPLEMENTARY INFORMATION:

Intellectual Property

1. U.S. Provisional Patent Application No. 62/095,322 filed on 12/
22/2014 which is entitled ``Mutant IDH1 Inhibitors Useful for 
Treating Cancer'' (HHS Ref. No. E-243-2014-0-US-01);
2. International Patent Application No. PCT/US2015/067406 filed on 
12/22/2015 which is entitled ``Mutant IDH1 Inhibitors Useful for 
Treating Cancer'' (HHS Ref. No. E-243-2014-0-PCT-02);
3. Australian Patent Application No. 2015369712 filed on 12/22/2015 
which is entitled ``Mutant IDH1 Inhibitors Useful for Treating 
Cancer'' which was issued as Patent No. 2015369712 on 8/20/2020 (HHS 
Ref. No. E-243-2014-0-AU-03);
4. Canadian Patent Application No. 2971872 filed on 12/22/2015 which 
is entitled ``Mutant IDH1 Inhibitors Useful for Treating Cancer'' 
(HHS Ref. No. E-243-2014-0-CA-04);
5. Chinese Patent Application No. 2015800763284 filed on 12/22/2015 
which is entitled ``Mutant IDH1 Inhibitors Useful for Treating 
Cancer'' which was issued as Patent No. ZL2015800763284 on 4/13/
2021'' (HHS Ref. No. E-243-2014-0-CN-05);
6. European Patent Application No. 15823901.2 filed on 12/22/2015 
which is entitled ``Mutant IDH1 Inhibitors Useful for Treating 
Cancer'' which issued as Patent No. 3237385 on 11/24/2021 and 
validated in Germany, Spain, France, Great Britain, and Italy (HHS 
Ref. No. E-243-2014-0-EP-06);
7. Japanese Patent Application No. 2017534314 filed on 6/22/2017 
which is entitled ``Mutant IDH1 Inhibitors Useful for Treating 
Cancer'' which was issued as Patent No. 6901394 on 6/21/2021 (HHS 
Ref. No. E-243-2014-0-JP-07);
8. U.S. Patent Application No. 15/538,570 filed on 12/12/2015 which 
is entitled ``Mutant IDH1 Inhibitors Useful for Treating Cancer'' 
which issued as Patent No. 10,703,746 on 7/7/2020 (HHS Ref. No. E-
243-2014-0-US-08);
9. U.S. Provisional Patent Application No. 62/353,298 filed on 6/22/
2016 which is entitled ``Mutant IDH1 Inhibitors Useful for Treating 
Cancer'' (HHS Ref. No. E-189-2016-0-US-01);
10. International Patent Application No. PCT/US2017/038549 filed on 
6/21/2017 which is entitled ``Mutant IDH1 Inhibitors Useful for 
Treating Cancer'' (HHS Ref. No. E-189-2016-0-PCT-02);
11. Australian Patent Application No. 2017281088 filed on 6/21/2017 
which is entitled ``Mutant IDH1 Inhibitors Useful for Treating 
Cancer'' which was issued as Patent No. 2017281088 on 9/9/2021 (HHS 
Ref. No. E-189-2016-0-AU-04);
12. Canadian Patent Application No. 3028999 filed on 6/21/2017 which 
is entitled ``Mutant IDH1 Inhibitors Useful for Treating Cancer'' 
(HHS Ref. No. E-189-2016-0-CA-05);
13. Chinese Patent Application No. 2017800514100 filed on 6/21/2017 
which is entitled ``Mutant IDH1 Inhibitors Useful for Treating 
Cancer'' which was issued as Patent No. 201780051410.0 on 9/20/2022 
(HHS Ref. No. E-189-2016-0-CN-06);
14. European Patent Application No. 17735296.0 filed on 6/21/2017 
which is entitled ``Mutant IDH1 Inhibitors Useful for Treating 
Cancer'' which issued as Patent No. 3475276 on 3/31/2021 and 
validated in Germany, Spain, France, Great Britain, and Italy (HHS 
Ref. No. E-189-2016-0-EP-07);
15. Japanese Patent Application No. 2018-567108 filed on 6/21/2017 
which is entitled ``Mutant IDH1 Inhibitors Useful for Treating 
Cancer'' which was issued as Patent No. 6987798 on 12/3/2021(HHS 
Ref. No. E-189-2016-0-JP-08); and
16. U.S. Patent Application No. 16/312,206 filed on 12/20/2018 which 
is entitled ``Mutant IDH1 Inhibitors Useful for Treating Cancer'' 
which was issued as Patent No. 10,836,759 on 11/17/2020 (HHS Ref. 
No. E-189-2016-0-US-03).

    The patent rights in these inventions have been either assigned 
and/or exclusively licensed to the government of the United States of 
America and the University of North Carolina at Chapel Hill.
    The prospective exclusive license territory may be worldwide, and 
the field of use may be limited to the following:
    ``Use of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitors, as 
claimed in the licensed patent rights, for the treatment of cancers 
(such as acute myeloid leukemia, glioma, cholangiocarcinoma, 
glioblastoma multiforme (GBM) and other solid tumors) and rare 
diseases.''
    The inventions relate to a series of novel compounds that potently 
and selectively inhibit mIDH1. These compounds reduce 2-HG levels in 
cell lines in vitro as well as in human cancer cells grown in mouse 
xenografts in vivo.
    These compounds show greater than 250-fold selectivity for the 
mutant enzyme over the wild-type, show favorable in vitro stability (in 
mouse, rat, dog and human hepatocyte exposure studies), are AMES 
negative, and exhibit no significant metabolic CYP liabilities. These 
compounds possess very favorable in vivo rodent pharmacokinetics and 
bioavailability and are well tolerated in rodents, even when dosed at 
high levels.
    Thus, the compounds of the subject inventions can be used 
individually or in combination to develop new therapies to treat 
diseases which result from mutant IDH1 activity. The diseases caused by 
mutant IDH1 activity include cancer (e.g., acute myeloid leukemia, 
glioma, cholangiocarcinoma and potentially other solid tumors) and 
selected rare diseases, such as Ollier Disease.
    This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and the prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published Notice, the National

[[Page 75297]]

Center for Advancing Translational Sciences receives written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 
404.
    In response to this Notice, the public may file comments or 
objections. Comments and objections, other than those in the form of a 
license application, will not be treated confidentially and may be made 
publicly available.
    License applications submitted in response to this Notice will be 
presumed to contain business confidential information and any release 
of information from these license applications will be made only as 
required and upon a request under the Freedom of Information Act, 5 
U.S.C. 552.

Joni L. Rutter,
Director, Office of the Director, National Center for Advancing 
Translational Sciences.
[FR Doc. 2023-24229 Filed 11-1-23; 8:45 am]
BILLING CODE 4140-01-P